Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7737215 | 0.91 | SLC6A4 (0.68) | SLC6A4SLC6A3SLC6A2ALDH1A1HTT | |
| SCHEMBL7741395 | 0.90 | SLC6A4 (0.67) | SLC6A4SLC6A3SLC6A2ALDH1A1SOS1 | |
| SCHEMBL3363248 | 0.90 | SLC6A4 (0.58) | SLC6A4CA12CA9ALDH1A1HTT | |
| SCHEMBL6946647 | 0.86 | SLC6A4 (0.76) | SLC6A4SLC6A3SLC6A2SOS1 | |
| SCHEMBL3363448 | 0.86 | SLC6A4 (0.67) | SLC6A4SLC6A3SLC6A2CA12CA9 | |
| SCHEMBL6943253 | 0.83 | SLC6A4 (0.70) | SLC6A4SLC6A3SLC6A2SOS1 | |
| SCHEMBL3363560 | 0.82 | SCN9A (0.58) | — | |
| SCHEMBL6947668 | 0.82 | SLC6A4 (0.69) | SLC6A4SLC6A3SLC6A2SOS1 | |
| SCHEMBL6947894 | 0.82 | SLC6A4 (0.69) | SLC6A4SLC6A3SLC6A2SOS1 | |
| SCHEMBL930692 | 0.82 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | SLC6A4 34/4885SLC6A3 226/4885SLC6A2 71/4885 |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | SLC6A4 4825/4885SLC6A3 4742/4885SLC6A2 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.